Showing recent highlights
What's New
PubMed (Open Access Guidelines) · December 1, 2026
A study looked at data from over 17,000 people with early-stage breast cancer to compare different chemotherapy combinations and schedules. Researchers found that certain combinations and timing of chemotherapy drugs — specifically giving some drugs together versus one after another — appeared to work better at helping people stay cancer-free and live longer. People with early-stage breast cancer may want to ask their doctor how the timing and combination of their chemotherapy plan compares to the latest research findings.
What's New
PubMed · November 2, 2026
A study found that using a smartphone app to track and manage side effects in women taking hormone-blocking treatment after early-stage breast cancer may be a cost-effective approach — meaning the benefits may be worth the money spent. Many women stop their breast cancer treatment early because of uncomfortable side effects, so finding affordable ways to help them stay on track could make a real difference in long-term outcomes. This is early research and hasn't yet changed treatment guidelines.
What's New
PubMed · November 2, 2026
Researchers found that for people with HER2-positive breast cancer (a type of breast cancer that grows faster because of a specific protein called HER2), combining a particular chemotherapy drug called PLD with two targeted therapies at the same time led to more patients seeing their tumors completely disappear before surgery — about 68% compared to 49% with a more traditional step-by-step approach. Importantly, the newer combination didn't appear to cause more heart-related side effects, which had been a longstanding concern with mixing these types of treatments. This is early research and hasn't yet changed treatment guidelines.
What's New
PubMed · November 2, 2026
Researchers found that people who get more sunlight exposure may have a lower chance of developing certain types of breast cancer, particularly a type called estrogen receptor-negative breast cancer — meaning the cancer doesn't rely on the hormone estrogen to grow. The link was strongest for a subtype called triple-negative breast cancer, which is often harder to treat, and people diagnosed during sunnier seasons also appeared to have better survival odds. This is early research and hasn't yet changed treatment guidelines.
What's New
PubMed · November 1, 2026
A study found that breast cancer survivors who took part in either an exercise program or an education program — where a doctor taught them about their health — saw lasting improvements in breast cancer-specific quality of life (how well they feel day-to-day in ways tied directly to their diagnosis) over 12 months. The education group felt better overall earlier on, at just 2 months in, compared to those who received standard care. However, the programs didn't show clear differences in anxiety or depression levels between the groups, so the full picture of how these programs help emotionally is still being worked out. This is early research and hasn't yet changed treatment guidelines.
What's New
PubMed · November 1, 2026
Researchers found that a newer type of breast screening called digital breast tomosynthesis — which takes multiple X-ray images to create a 3D-like picture of the breast — was compared to standard mammography to see how often cancers were missed at screening and then showed up later (called interval cancers). This matters because catching cancer early rather than between screenings can make a real difference in treatment options and outcomes for people with breast cancer. This is early research and hasn't yet changed treatment guidelines.
What's New
PubMed · November 1, 2026
Researchers found that women with breast cancer who had higher levels of a protein called CA15-3 in their blood before surgery were significantly more likely to have cancer that had spread to nearby lymph nodes — the small glands under the arm that help fight infection. This matters because spread to those lymph nodes is one of the strongest signs of how serious the cancer may be, and right now doctors can only check for it through an invasive procedure that involves cutting into the body. This is early research and hasn't yet changed treatment guidelines.
What's New
PubMed · November 1, 2026
A study found that plant-based compounds called phytoestrogens — naturally found in foods like soy and flaxseed — may have a slight effect on estrogen levels in people with breast cancer, but the results were not strong enough to draw firm conclusions. Researchers looked at several studies involving nearly 1,700 patients and found that phytoestrogens did not clearly reduce the chances of cancer coming back. This is early research and hasn't yet changed treatment guidelines.
What's New
PubMed · November 1, 2026
A study found that breast cancer survivors who took part in a six-session mindful eating program — which teaches people to pay closer attention to hunger, fullness, and emotions around food — showed improvements in their eating habits and had a lower body weight over time compared to those who didn't take part in the program. Both groups in the study got better at recognizing hunger and fullness cues, but the mindful eating group also saw a gradual reduction in BMI (a measure of body weight relative to height) over six months. This is early research and hasn't yet changed treatment guidelines.
What's New
PubMed · November 1, 2026
Researchers found that when people with breast cancer receive chemotherapy before surgery to shrink their tumor — making it possible to remove just the tumor rather than the whole breast — about 1 in 10 patients still had cancer cells at the very edge of the removed tissue, meaning the surgeon may not have gotten it all. When that happens, some patients needed a second operation to remove more tissue, and that occurred in roughly 1 in 7 cases overall, though the number varied a lot depending on the hospital. Certain tumor types, including a slower-growing type called lobular carcinoma, were more likely to leave those tricky edges. This is early research and hasn't yet changed treatment guidelines.
What's New
PubMed · November 1, 2026
Researchers found that a type of cancer treatment called antibody-drug conjugates — which are specially designed drugs that deliver chemotherapy directly to cancer cells — showed promising results when given to people with early-stage breast cancer before surgery. In the studies reviewed, about 38 out of 100 patients showed no remaining cancer in their tissue after treatment (called a complete response), with the best results seen in people whose tumors tested positive for a protein called HER2. This is early research and hasn't yet changed treatment guidelines.
What's New
PubMed · November 1, 2026
Researchers found that a specialized type of radiation called proton beam therapy — aimed directly at a breast tumor without surgically removing it first — shrank tumors and prevented them from coming back in a small group of women with early-stage breast cancer over a five-year follow-up period. Most patients tolerated the treatment well, with only mild skin reactions like redness or small visible blood vessels near the skin's surface. This is exciting because it raises the possibility that some women might one day be able to treat early breast cancer without surgery, though this is early research and hasn't yet changed treatment guidelines.
Medications
PubMed · November 1, 2026
Researchers found that a newer targeted treatment called trastuzumab botidotin — which delivers cancer-fighting medicine directly to HER2-positive breast cancer cells (a type of breast cancer that has a specific protein making it grow faster) — worked better than an existing treatment called Kadcyla (trastuzumab emtansine). In the study, patients who received trastuzumab botidotin went more than twice as long without their cancer getting worse — about 11 months compared to about 4 months for those on Kadcyla. This appears to be a new treatment option that was tested head-to-head against a well-known therapy, and the results were consistent across different groups of patients in the study.
What's New
PubMed · November 1, 2026
Researchers found that using artificial intelligence to help read mammograms — the X-rays used to screen for breast cancer — may help catch more cancers compared to standard reading by two radiologists alone, across nearly 600,000 screening exams in Europe. The AI support also showed potential to reduce the workload on radiologists, who are in short supply in many countries, without meaningfully increasing the number of women called back unnecessarily for extra tests. This is early research and hasn't yet changed treatment guidelines.
What's New
PubMed · November 1, 2026
Researchers found that a shorter, faster version of breast MRI — which takes less time in the scanner than a standard full MRI — can detect breast cancer about as accurately as the longer version, especially when certain extra image sequences are added. This matters because a quicker MRI scan could make it easier and more affordable for more people to get high-quality breast imaging. This is early research and hasn't yet changed treatment guidelines.
What's New
PubMed · November 1, 2026
Researchers found that approved AI tools designed to help read mammograms performed quite well at spotting breast cancer — correctly identifying it about 76% of the time and correctly giving the all-clear about 90% of the time. When AI was woven into the screening process, it caught just as many cancers as having two radiologists review every scan, while also reducing how much work radiologists had to do. This is early research and hasn't yet changed treatment guidelines.
What's New
PubMed · November 1, 2026
A study found that women newly diagnosed with breast cancer who received special nurse-led coaching sessions — designed to help them change negative thought patterns about why bad things happen to them — showed improvements in resilience (the ability to bounce back emotionally) and healthier ways of coping compared to women who received standard nursing care alone. The coaching was delivered through a mix of in-person meetings and ongoing support through a mobile app, making it easier to access during a difficult time right after diagnosis. This is early research and hasn't yet changed treatment guidelines.
What's New
PubMed · November 1, 2026
Researchers found that AI models trained to read MRI and ultrasound images can predict whether breast cancer has spread to nearby lymph nodes — the small glands under the arm that doctors check to understand how far a cancer has traveled — with moderate accuracy. The best results came when two types of AI approaches were combined, reaching accuracy scores as high as 0.92, though the models weren't strong enough on their own to replace current testing methods like a surgical biopsy. This is early research and hasn't yet changed treatment guidelines.
What's New
PubMed · November 1, 2026
Researchers found that people with breast cancer who had a nipple-sparing mastectomy — a surgery that removes breast tissue while keeping the nipple intact — had slightly better overall survival rates compared to those who had more traditional mastectomy approaches that remove the nipple. The study, which pulled together results from 60 studies and over 7,700 patients followed for up to a decade, also found that cancer coming back in the nipple area was uncommon, suggesting the procedure may be oncologically safe — meaning it doesn't appear to increase the risk of cancer returning. This is early research and hasn't yet changed treatment guidelines.
Guidelines
PubMed · November 1, 2026
According to Canadian Association of Radiologists (CAR) guidelines, breast ultrasound should be used in specific, well-defined ways as part of a complete breast imaging plan — including helping to diagnose concerns, adding extra screening in certain situations, and guiding procedures like biopsies. The guidelines stress that ultrasound results should always be looked at alongside other imaging, like mammograms, and that findings should be reported in a clear, standardized way to help ensure nothing is missed or delayed. Because patient needs and available resources can vary, the radiologist reviewing the images is ultimately responsible for deciding how the guidelines apply in each individual case.
Guidelines
PubMed · November 1, 2026
According to the Canadian Association of Radiologists (CAR) guidelines, a specialized imaging technique called contrast-enhanced mammography (CEM) — which uses a dye injected into the bloodstream to make breast tissue easier to see on a mammogram — is recommended for situations like planning surgery, solving tricky diagnostic questions, or screening when breast MRI (a type of detailed scan) is not available or suitable for a patient. These guidelines matter because they set clear standards for how the imaging should be done, how results should be reported, and how to keep patients safe throughout the process. The guidelines also note that every patient's situation is different, and the radiologist overseeing the scan is responsible for using their professional judgment alongside these recommendations.
What's New
PubMed · November 1, 2026
Researchers found that a targeted treatment called trastuzumab deruxtecan (T-DXd) — a drug that delivers chemotherapy directly to cancer cells — helped people with HER2-positive and HER2-low breast cancer live longer and kept their cancer from getting worse, compared to other treatments. HER2 is a protein found in higher amounts on some breast cancer cells, and about 1 in 5 breast cancer cases involve it. However, the researchers also found that this treatment came with notable side effects, including a significantly higher risk of a serious lung condition called interstitial lung disease (scarring or inflammation in the lungs), as well as heart changes, nausea, hair loss, and low red blood cell counts — so careful monitoring by a doctor would be important. This is early research and hasn't yet changed treatment guidelines.
What's New
PubMed · October 28, 2026
A study found that giving people with early-stage breast cancer a app that checked in on how they were feeling each week — and automatically alerted their care team if things got worse — did not clearly improve their overall quality of life compared to using a supportive app alone with less frequent check-ins. Researchers looked at many aspects of wellbeing, like pain, sleep, and emotional health, and found no consistent difference between the two approaches. This is early research and hasn't yet changed treatment guidelines.
Medications
The Lancet · October 26, 2026
A study found that a drug called izalontamab brengitecan (also called iza-bren) helped people with a specific type of breast cancer — called HR-positive, HER2-negative — live longer without their cancer getting worse, compared to standard chemotherapy. This was for patients who had already tried hormone-based treatments, certain targeted drugs, and one or two rounds of chemotherapy. Researchers suggest this could be a new treatment option, though it has so far only been studied in patients in China, and more research is needed to understand how well it works in wider populations and earlier in treatment.
What's New
NEJM · October 24, 2026
Researchers found that combining two targeted treatments — anbenitamab and HB1801, both designed to attack a specific protein called HER2 that fuels certain breast cancer cells — showed promising results in people with advanced HER2-positive breast cancer, a type that tends to grow more aggressively. This matters because some patients with this form of breast cancer run out of options when standard treatments stop working, so new combinations that might slow or shrink the cancer are an important area of research. This is early research and hasn't yet changed treatment guidelines.
What's New
PubMed · October 23, 2026
A study found that a mindfulness-based training program — focused specifically on intimacy and sexuality — appeared to improve sexual well-being in women who had been treated for breast cancer, a group that often struggles with these challenges due to treatment side effects. The program involved eight weekly group sessions and was compared to women who received no such training. This is early research and hasn't yet changed treatment guidelines.
What's New
PubMed · October 20, 2026
Researchers found that in people with a type of breast cancer that tests positive for a protein called HER2, certain tumor characteristics — like being negative for estrogen receptors — were linked to better responses to a combination of chemotherapy and targeted treatments given before surgery, meaning more tumors showed no signs of cancer by the time of the operation. About 64% of patients with HER2-positive, estrogen receptor-negative tumors showed this strong response, compared to around 32% of those whose tumors were also estrogen receptor-positive, which may help doctors and patients better understand what to expect from this treatment approach. This is early research and hasn't yet changed treatment guidelines.
Guidelines
PubMed · October 20, 2026
According to the American Society of Clinical Oncology (ASCO) guidelines, people who have completed primary breast cancer treatment should have regular check-ups that include a physical exam and mammography — an X-ray of the breast used to look for signs of cancer returning — and these visits can be done either in person or virtually. ASCO also recommends that people at higher risk of their cancer coming back, such as those whose cancer had spread more widely or who had cancer cells remaining after chemotherapy, should be monitored more closely and more often. These guidelines matter because staying on a consistent follow-up schedule gives doctors the best chance of catching any signs of recurrence early, when it is often easier to treat.
Ask your doctor: Ask the doctor whether the patient should follow the ASCO guideline recommendations for how often to get mammograms and other check-ups after completing primary breast cancer treatment.
What's New
PubMed · October 20, 2026
Researchers found that combining a drug called entinostat with a hormone-blocking treatment called exemestane may help people with a certain type of advanced breast cancer — one that is fueled by hormones and has stopped responding to standard hormone therapy — live longer and go longer before needing harsher treatments like chemotherapy. In the study, patients who received the combination lived a median of about 38.6 months compared to 29.2 months for those who did not get entinostat, though the difference was not statistically conclusive, meaning it could have occurred by chance. This is early research and hasn't yet changed treatment guidelines.
What's New
PubMed · October 16, 2026
Researchers found that for women over 50 with early-stage breast cancer that is hormone receptor-positive and HER2-negative — even those with larger tumors, faster-growing cancer cells, or a small number of affected lymph nodes — a genetic test called MammaPrint that showed low risk was a strong signal that skipping additional chemotherapy was safe. After about 8 to 9 years of follow-up, the vast majority of patients in these higher-risk groups who skipped chemotherapy remained free of cancer spreading to distant parts of the body, and adding chemotherapy made little to no meaningful difference in outcomes. This is early research and hasn't yet changed treatment guidelines.
For informational purposes only. Not medical advice. Always consult a physician before making any health decisions.